SurmodiCs Pounce Venous THrOMbectomy System Post Market Clinical Follow Up Study

Trial statusNot yet recruiting
Trial phaseNot applicable
Trial typeInterventional
Biological sexAll
AgeNot listed
SponsorSurModics, Inc.

About this trial

This is an open label, prospective, non-randomised, multi-centre post market study of the POUNCE Venous Thrombectomy system for de-clotting in the peripheral vasculature (e.g., iliofemoral veins).

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

Individuals aged 18 years or older

Patients with peripheral vascular thrombus (e.g., iliofemoral) as confirmed by Doppler Ultrasonography (DUS)

Voluntary informed written consent, given before performance of any clinical investigation-related procedure not part of standard medical care, and with the understanding that consent may be withdrawn at any time without prejudice to future medical care

Patients who would likely experience benefit from mechanical thrombus removal

Disqualifiers

Presence of a stent in the target vein

Known aggressive hypercoagulable states such as antiphospholipid antibody syndrome, Protein C/S Deficiency, Antithrombin deficiency, homozygous prothrombin gene mutation or homozygous Factor V Leiden

Limb-threatening circulatory compromise

Known symptomatic Pulmonary Embolism at the time of enrollment with or without severe RV dysfunction

Trial design

Design model

Single group

Treatments tested in this trial

  • Pounce Venous Thrombectomy System

    Device

    The device is indicated for mechanical de-clotting and controlled and selective infusion of physician specified fluids, including thrombolytics, in the peripheral vasculature.

Treatment groups

40 Participants
are divided into 1 treatment group
Group A: Pounce Venous Thrombectomy SystemOther 1 intervention

Trial outcomes

Primary outcomes

1

Device Performance

Successful preparation and use of the device to achieve flow restoration, i.e., elimination of a minimum of 50% thrombus (SIR Grade II or Grade III) in the treated target venous segment.

Time frame
30 days, 1 year

Secondary outcomes

Other outcomes

Locations

This trial has no locations.

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

This trial is not recruiting at the moment. You can still explore other options: